Researchers at Stanford have developed a combination therapy to treat neuroblastoma, the most common and deadly solid tumor in childhood. Neuroblastoma derives from neural crest cells that fail to exit the cell cycle and differentiate.
Engineers at the Khuri-Yakub Group have designed a non-surgical alternative for treating epilepsy using ultrasonic technology which can detect, localize, and suppress epileptic seizures in epileptic patients.
Researchers at Stanford are developing methods of using arginine vasopressin (AVP) to improve social abilities of children with autism spectrum disorder (ASD). Autism is a neurodevelopmental disorder characterized by social impairments (e.g.
Researchers in Dr. Anton Wyss-Coray's lab have identified a new therapeutic avenue for treatment of age-related neurodegenerative diseases. Cerebrovascular changes and inflammation are key features of brain aging and neurodegeneration.
Researchers in Dr. Karl Deisseroth's lab have engineered a channelrhodopsin variant that can be stimulated by red light and has fast stimulation frequencies. In neurons, channelrhodopsins are light activated protein channels that induce action potential firing.
Researchers in Prof. Michelle Monje-Deisseroth's laboratory have discovered a previously unknown mechanism for glioma tumor growth and invasion that defines a novel set of therapeutic targets.
To better understand how the brain processes information and generates behavior, researchers in Dr. Liqun Luo's lab have generated the FosTRAP and ArcTRAP mouse strains.
Researchers in Dr. Karl Deisseroth's lab have created inhibitory channelrhodopsins (ChRs) that allow fast, reversible inhibition of electrical signals in neurons. Optogenetics is a technique used to understand normal and pathological neural circuitry.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.